<DOC>
	<DOCNO>NCT02683863</DOCNO>
	<brief_summary>The purpose study explore whether DMF ( Dimethyl Fumarate ) MMF ( monomethyl fumarate ) main bioactive metabolite , capable enter central nervous system SPMS patient treat Tecfidera® . PK sample ( pharmacokinetics - amount study drug blood ) test compare PK sample , amount study drug , spinal fluid ( CSF ) .</brief_summary>
	<brief_title>Pharmacokinetics DMF Effects DMF Exploratory Biomarkers</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Inclusion Criteria ( MS Population ) : To eligible participate study , candidate must meet following eligibility criterion screen , timepoint specify individual eligibility criterion list : 1 . Ability understand purpose risk study provide sign date informed consent authorization use protect health information ( PHI ) accordance national local patient privacy regulation . Subjects must provide separate inform consent participate CSF study . 2 . Aged 25 65 yearsold , inclusive , time informed consent . 3 . Male female subject confirm diagnosis SPMS . 4 . EDSS score 3 7 , inclusive , screen . 5 . Weight 130 200 lb . Exclusion Criteria ( MS Population ) Candidates exclude study entry follow exclusion criterion exist screen , timepoint specify individual criterion list : 1 . Unable unwilling provide inform consent . ( Subjects must provide separate inform consent study . ) 2 . A MS relapse , determine Investigator , occur within 90 day prior screen , subject stabilize previous relapse prior screen . 3 . Any contraindication brain magnetic resonance imaging ( MRI ) ( e.g. , pacemaker , MRIincompatible aneurysm clip , artificial heart valve , metal foreign body ; claustrophobia medically manage ) contraindication administration gadoliniumcontrast agent . 4 . Clinically significant brain MRI finding related MS , judge Investigator , screen . 5 . Any contraindication LP ( e.g. , aspirin great 325 mg/day , warfarin , clopidrogel , decrease platelet count , prolong PT PTT 1 ½ normal ) determine history Investigator decision . 6 . Evidence history autoimmune disease ( e.g. , rheumatoid arthritis , systemic lupus erythematosus , ulcerative colitis , diabetes mellitus ) exception MS. 7 . Any sign chronic active infection , require antibiotic treatment ( refer Exclusion 23 ) ( e.g. , urinary tract infection , bronchitis , hepatitis , tuberculosis ) except require topical medication treatment ( e.g. , athlete foot ) , screen laboratory evidence consistent significant chronic active acute infection require systemic treatment . 8 . Pregnant ; breastfeed female ; male father potential female childbearing potential unwilling unable use effective method contraception outline protocol ( Section 12.5 ) duration study least 28 day last dose DMF use protocol . For female childbearing potential , positive pregnancy test time within protocol . 9 . Known positive human immunodeficiency virus antibody , hepatitis B surface antigen , hepatitis B core antibody , hepatitis C antibody test indicative present prior infection . 10 . Any abnormal hematology value clinical chemistry value judge Investigator Sponsor clinically significant , include white blood cell count ( WBC ) 3500/mm3 , absolute lymphocyte count lower limit normal . 11 . Positive QuantiferonTuberculosis Gold InTube test ( QFTGIT ) screen know history active tuberculosis adequately treat . 12 . Any malignancy within 5 year , except basal squamous cell skin lesion surgically excise , evidence metastasis . 13 . Any clinical , CSF , MRI evidence progressive multifocal leukoencephalopathy , historical MRI . 14 . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment Investigator , would make subject inappropriate entry study . 15 . Subjects participate expect participate interventional clinical trial , except participate Study USBGTUS10766 site . 16 . History drug alcohol abuse ( define Investigator ) within 2 year prior screen . Exclusion Criteria Related Medication 17 . Previous exposure DMF disease management time past . 18 . History severe allergic anaphylactic reaction know drug hypersensitivity fumaric acid fumaric acid ester . 19 . Treatment methylprednisolone systemic corticosteroid MS relapse otherwise within 30 day prior Day 1 study treatment . 20 . Treatment MS disease modify therapy follow : Beta interferon ( interferon beta1a [ Avonex® Rebif® ] interferon beta1b [ Betaseron® ] , glatiramer acetate [ Copaxone® ] within 6 week prior Baseline . Fingolimod ( Gilenya® ) , teriflunomide ( Aubagio® ) within 6 month prior Baseline , except teriflunomide washout accelerate elimination verification zero serum level teriflunomide prior Baseline . Natalizumab ( Tysabri® ) within 6 month prior Screening OR 1 month prior screen subject positive Nabs ( neutralize antibody ) Tysabri® Treatment within past 5 year current treatment follow agent : cyclosporine , cladribine , agent immunosuppressive ( e.g. , entanercept ) , murine protein , Tcell vaccination ) , stem cell transplantation prior Screening . Treatment within past 2 year rituximab , IVIG , mycophenolate 21 . Receipt nonlive vaccine within previous 14 day live vaccine within 30 day prior first dose study treatment . 22 . Treatment investigational drug within 30 day 5 halflives precede first dose study treatment , whichever longer . 23 . Use antibiotic reason within 3 month Screening . Inclusion Criteria ( Normal Control Volunteers Only ) To eligible participate study , normal control candidate must meet following eligibility criterion screen : 1 . Ability understand purpose risk study provide sign date informed consent authorization use protect health information ( PHI ) accordance national local patient privacy regulation . Subjects must provide separate inform consent participate CSF study . 2 . Male female , age 25 65 yearsold , inclusive , time informed consent . 3 . Weight 130 200 lb . Exclusion Criteria ( Normal Control Volunteers Only ) Normal control candidate exclude study entry follow exclusion criterion exist screen , timepoint specify individual criterion list : 1 . Unable unwilling provide inform consent . ( Subjects must provide separate inform consent study . ) 2 . Any contraindication LP ( e.g. , aspirin great 325 mg/day , warfarin , clopidrogel , decrease platelet count , prolong PT PTT 1 ½ normal ) determine history Investigator decision . 3 . Evidence history autoimmune disease ( e.g. , rheumatoid arthritis , systemic lupus erythematosus , ulcerative colitis , diabetes mellitus ) exception MS. 4 . Any sign chronic active infection , require antibiotic treatment ( refer Exclusion 23 ) ( e.g. , urinary tract infection , bronchitis , hepatitis , tuberculosis ) except require topical medication treatment ( e.g. , athlete foot ) , screen laboratory evidence consistent significant chronic active acute infection require systemic treatment . 5 . Pregnant ; breastfeed female ; male father potential female childbearing potential unwilling unable use effective method contraception outline protocol ( Section 12.5 ) duration study least 28 day last dose DMF use protocol . For female childbearing potential , positive pregnancy test time within protocol . 6 . Known positive human immunodeficiency virus antibody , hepatitis B surface antigen , hepatitis B core antibody , hepatitis C antibody test indicative present prior infection . 7 . Any abnormal hematology value clinical chemistry value judge Investigator Sponsor clinically significant , include white blood cell count ( WBC ) 3500/mm3 , absolute lymphocyte count lower limit normal . 8 . Positive QuantiferonTuberculosis Gold InTube test ( QFTGIT ) screen know history active tuberculosis adequately treat . 9 . Any malignancy within 5 year , except basal squamous cell skin lesion surgically excise , evidence metastasis . 10 . Any clinical , CSF , MRI evidence progressive multifocal leukoencephalopathy , historical MRI . 11 . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment Investigator , would make subject inappropriate entry study . 12 . Subjects participate expect participate interventional clinical trial , except participate Study USBGTUS10766 site . 13 . History drug alcohol abuse ( define Investigator ) within 2 year prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>